Colin Greineder, MD, PhD


Dr. Greineder attended the Yale School of Medicine and completed Emergency Medicine residency at the University of Michigan. After a year working in the community, he returned to academia to pursue a PhD in Pharmacology and post-doctoral fellowship at the University of Pennsylvania. Throughout this long period of scientific training, Dr. Greineder continued to work as an attending in a variety of academic and community ERs, including UPenn, Thomas Jefferson, Geisinger Medical Center, and the Crozer-Keystone Health System. He was awarded a K08 Career Development award from the NHLBI and returned to Michigan Medicine in 2018 as a tenure track faculty in Emergency Medicine and Pharmacology. Dr. Greineder’s laboratory focuses on development of novel pharmacologic therapies for the treatment of emergent ischemic, thrombotic, and inflammatory disorders. The primary focus is affinity ligand delivery of biotherapeutics to endothelial cells as a means of restoring their homeostatic functions and elucidating their role in disease pathogenesis. Additional interests include pharmacokinetic modeling, coagulofibrinolytic changes in critical illness, and risk stratification and management of venous thromboembolism.